Vivoryon Therapeutics AG Stock Euronext Amsterdam
Equities
DE0007921835
Biotechnology & Medical Research
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 10.99M 11.73M |
---|---|---|---|---|---|
Net income 2023 * | -23M -24.55M | Net income 2024 * | -18M -19.21M | EV / Sales 2023 * | - |
Net cash position 2023 * | 24.1M 25.72M | Net cash position 2024 * | 19.55M 20.86M | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.51
x | P/E ratio 2024 * |
-0.66
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.82% |
Latest transcript on Vivoryon Therapeutics AG
Managers | Title | Age | Since |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 18-08-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 74 | 06-12-31 | |
Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
1st Jan change | Capi. | |
---|---|---|
-1.78% | 41.71B | |
+47.70% | 41.56B | |
+4.01% | 39.74B | |
-15.14% | 25.61B | |
+3.16% | 24.26B | |
-24.08% | 18.55B | |
-2.67% | 11.93B | |
+24.76% | 11.93B | |
+7.01% | 10.91B |